Trial News & Events

Progress coming in amyotrophic lateral sclerosis, but rigorous studies needed

The community of individuals living with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, has endured many false hopes for promising therapies and is still waiting for the first disease-modifying drug. Nevertheless, "we have made huge progress in the last decade in ALS," Merit Cudkowicz, professor of neurology at Harvard Medical School and chief of the neurology service and director of the MDA ALS Clinic at Massachusetts General Hospital, told participants in an integrated neuroscience session on ALS at the American Academy of Neurology (AAN) 67th annual meeting. Read the entire article here.